newsfilter
← Latest News
GlobeNewswire·

TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial- IND Clearance for Phase 1/2 clinical trial of TC-510- 30 patients treated with gavo-cel in the expanded Phase 1 trial; dataset review in July 2022- Updates anticipated in the s